Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + ketamine
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Perineural, Epidural, Caudal
01
Overview
A combination of ropivacaine, an amide-type local anesthetic, and ketamine, an NMDA receptor antagonist. This combination is used for regional anesthesia and pain management, particularly in nerve blocks. Ropivacaine blocks sodium channels to prevent nerve impulse generation and conduction, while ketamine provides additional analgesia through NMDA receptor antagonism. The combination has shown enhanced analgesic efficacy and prolonged duration of action in certain applications compared to either agent alone.
- Other names
- local anesthetic-ketamineropivacaine-ketamine combination
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ropivacaine + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropivacaine + ketamine.